On Wednesday, the company announced it had terminated its license for Aduhelm (aducanumab) and will stop all development and commercialization activities.
The drug is intended to work against the clumps of misfolded beta-amyloid protein that accumulate in the brains of people with Alzheimer's. Though a small, early clinical trial showed the drug could reduce plaques in the brains of people with Alzheimer's, it initially failed two identically designed Phase 3 trials.
[
add
]
[
|
|
...
]